Startups
Growing Industries Month 2019

Christiana Care seeks FDA approval for CRISPR cancer trial

The gene editing tool could potentially save lives.

Gene editing could be used to fight cancer before long. (Courtesy YouTube)

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), the gene-editing tool, has been the subject of countless debates on the ethical use of a technology that can actually alter DNA — with some foreseeing a dystopia of custom-ordered babies and miniature giraffes as pets.

Less dystopian are the potential medical benefits of CRISPR, which is why the Christiana Care Health System’s Gene Editing Institute is in the process of developing its first clinical trial that would use CRISPR on patients, after conducting successful lab trials. (You can read the December 2018 proof of concept paper on Molecular Therapy Oncolytics.)

The institute recently filed a preliminary investigational new drug application (IND) with the U.S. Food and Drug Administration. If approved, the trial, which focuses on treatment of  KRAS-positive non-small cell lung cancer, would have cleared a major hurdle in starting the trial.

“This exciting study represents a trio of firsts,” said Nicholas J. Petrelli, M.D., FACS, medical director of Christiana Care’s Helen F. Graham Cancer Center & Research Institute, in a statement. “It will be the first lung cancer clinical trial carried out by a gene editing program embedded in a community cancer center. While our Gene Editing Institute has a great deal of translational research experience, this will be its first study to move scientific discovery toward an IND application.

“And, it will also be the first time that we will be investigating technology that was grown organically at the Gene Editing Institute.”

You can learn more about CRISPR here:

This editorial article is a part of Technical.ly's Growing Industries month, when Technical.ly Delaware is focusing extra reporting on the topic of biotech.

Companies: ChristianaCare
25% to our goal! $25,000

Before you go...

To keep our site paywall-free, we’re launching a campaign to raise $25,000 by the end of the year. We believe information about entrepreneurs and tech should be accessible to everyone and your support helps make that happen, because journalism costs money.

Can we count on you? Your contribution to the Technical.ly Journalism Fund is tax-deductible.

Donate Today
Engagement

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!

Trending

The person charged in the UnitedHealthcare CEO shooting had a ton of tech connections

The looming TikTok ban doesn’t strike financial fear into the hearts of creators — it’s community they’re worried about

What a new innovation index tells us about Delaware

Dogfish Head founder says he’s still against beer conglomerates, despite getting acquired

Technically Media